Table 1 Baseline patient characteristics.
| Characteristics | Baseline patient characteristics for all enrolled patients | Baseline patient characteristics for patients who entered the extension study | |||
|---|---|---|---|---|---|
| Placebo (n = 112) | Etoricoxib 60 mg (n = 446) | Naproxen (n = 439) | Etoricoxib (n = 246) | Naproxen (n = 217) | |
| Gender, No (%) | |||||
| Female | 82 (73.2) | 322 (72.2) | 314 (71.5) | 191 (77.6) | 156 (71.9) |
| Male | 30 (26.8) | 124 (27.8) | 125 (28.5) | 55 (22.4) | 61 (28.1) |
| Race, No (%) | |||||
| Asian | 1 (0.9) | 2 (0.4) | 3 (0.7) | 1 (0.4) | 1 (0.5) |
| Black | 6 (5.4) | 18 (4.0) | 19 (4.3) | 10 (4.1) | 5 (2.3) |
| Multiracial | 6 (5.4) | 24 (5.4) | 20 (4.6) | 26 (10.6) | 19 (8.8) |
| Other | 10 (8.9) | 42 (9.4) | 35 (8.0) | 31 (12.6) | 22 (10.1) |
| White | 89 (79.5) | 360 (80.7) | 362 (82.5) | 178 (72.4) | 170 (78.3) |
| Age (years) | |||||
| Mean (SD) | 63.8 (10.2) | 62.59 (9.8) | 62.7 (9.7) | 62.19 (9.0) | 61.51 (9.4) |
| Range | 40 to 87 | 35 to 92 | 40 to 87 | 40 to 84 | 40 to 87 |
| Body weight (kg) | |||||
| Mean (SD) | 86.4 (18.5) | 84.28 (18.9) | 85.09 (18.9) | 83.90 (18.67) | 86.03 (18.44) |
| Range | 51.3 to 138.0 | 44.8 to 176.9 | 48.00 to 158.8 | 47.6 to 176.9 | 48.0 to 142.9 |
| Primary OA joint, No (%) | |||||
| Hip | 20 (17.9) | 100 (22.4) | 99 (22.6) | 40 (16.3) | 38 (17.5) |
| Knee | 92 (82.1) | 346 (77.6) | 340 (77.4) | 206 (83.7) | 179 (82.5) |
| ARA function class, No (%) | |||||
| I | 24 (21.4) | 99 (22.2) | 90 (20.5) | 48 (19.5) | 48 (22.1) |
| II | 69 (61.6) | 246 (55.2) | 269 (61.3) | 144 (58.5) | 126 (58.1) |
| III | 19 (17.0) | 101 (22.6) | 80 (18.2) | 54 (22.0) | 43 (19.8) |
ARA, American Rheumatism Association.